GREVEN SIMONE
No ORCID on file
· 91 papers in corpus
· active 2011
Frequent coauthors
- WOLF SIEGMUND 78
- BRUDER SANDRA 78
- FREIBERG CHRISTOPH 78
- HARRENGA AXEL 78
- OTTO CHRISTIANE 78
- TRAUTWEIN MARK 78
- WILMEN ANDREAS 39
- EICKER ANDREA 39
- OTTO CHRISTIANE DR DR 13
- TRAUTWEIN MARK DR 13
2011
The present invention is directed to neutralizing prolactin receptor antibodies and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications medi…
2011
The present invention is directed to neutralizing prolactin receptor antibodies and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications medi…
2011
The present invention is directed to neutralizing prolactin receptor antibodies and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications medi…
2011
The present invention is directed to neutralizing prolactin receptor antibodies and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications medi…
2011
The present invention is directed to neutralizing prolactin receptor antibodies and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications medi…
2011
The present invention is directed to neutralizing prolactin receptor antibodies and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications medi…
2011
The present invention is directed to neutralizing prolactin receptor antibodies and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications medi…
2011
The present invention is directed to neutralizing prolactin receptor antibodies and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications medi…
2011
The present invention is directed to neutralizing prolactin receptor antibodies and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications medi…
2011
The present invention is directed to neutralizing prolactin receptor antibodies and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications medi…
2011
The present invention is directed to neutralizing prolactin receptor antibodies and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications medi…
2011
The present invention is directed to neutralizing prolactin receptor antibodies and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications medi…
2011
The present invention is directed to neutralizing prolactin receptor antibodies and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications medi…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 005- C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 005- C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 006- H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 006- H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 002- H08, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 002- H08, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 006- H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to pharmaceutical compositions containing one or more neutralizing prolactin receptor antibodies and antigen binding fragments, and their use in the treatment or prevention of benign disorders and indicatio…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 002- H06, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to pharmaceutical compositions containing one or more neutralizing prolactin receptor antibodies and antigen binding fragments, and their use in the treatment or prevention of benign disorders and indicatio…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 002- H06, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to pharmaceutical compositions containing one or more neutralizing prolactin receptor antibodies and antigen binding fragments, and their use in the treatment or prevention of benign disorders and indicatio…